BeiGene, Ltd. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2017. The filing identifies the registrant as BeiGene, Ltd.; the request metadata names “Beone Medicines Ltd.” Amounts below are U.S. dollars unless stated otherwise. Financial statement amounts are in thousands, converted here to millions where useful.
Business context
BeiGene is a clinical-stage biopharmaceutical company focused on oncology. It had no approved products and no product-sale revenue. Its principal clinical-stage candidates were BGB-3111, BGB-A317, BGB-290 and BGB-283. The company reported that it had demonstrated proof-of-concept for its molecularly targeted candidates in defined patient populations; these candidates remained in development.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Revenue | $0 | $0.7 million |
| Research and development expense | $42.8 million | $17.9 million |
| General and administrative expense | $8.8 million | $3.1 million |
| Operating loss | $51.5 million | $20.3 million |
| Net loss | $50.6 million | $22.0 million |
| Basic and diluted loss per ordinary share | $0.10 | $0.07 |
| Basic and diluted loss per ADS | $1.27 | $0.97 |
| Cash used in operating activities | $35.7 million | $19.8 million |
There was no meaningful operating margin to report given the absence of revenue and ongoing operating losses. The company attributed increased expenses mainly to expanded clinical development, hiring, share-based compensation and public-company and professional costs.
At March 31, 2017, cash and cash equivalents were $97.8 million and short-term investments, primarily U.S. Treasury securities, were $229.7 million, totaling $327.5 million. Current assets were $336.2 million and current liabilities $50.0 million. Total liabilities were $68.3 million; debt comprised a $2.5 million short-term loan and a $17.4 million long-term bank loan. The long-term loan bears fixed interest at 7%, is secured by equipment and patent rights, and is repayable in 2018 and 2019. Shareholders’ equity was $308.4 million and accumulated deficit was $288.0 million.
Investing activities provided $43.5 million, primarily reflecting proceeds from sales or maturities of available-for-sale securities, partly offset by property and equipment purchases and a Guangzhou land-auction deposit. Financing activities provided $2.5 million, including a short-term loan and option exercises; Q1 2016 financing had included IPO proceeds. Cash and short-term investments declined from $368.2 million at December 31, 2016 to $327.5 million at March 31, 2017.
Material changes and notable items
- Revenue fell to zero as previously recognized collaboration revenue from Merck KGaA had run off; Phase 1 services associated with BGB-283 were completed by mid-2016.
- In March 2017, Merck KGaA declined to exercise a continuation option for BGB-283 outside China. BeiGene regained worldwide rights after the ex-PRC agreement terminated, subject to surviving provisions. BeiGene remained eligible for specified PRC clinical milestones.
- R&D expense increased $24.9 million year over year, including higher external clinical-program costs, especially for BGB-3111 and BGB-A317, and higher internal personnel and share-based compensation expenses. G&A expense rose $5.7 million.
- BeiGene established a Guangzhou biologics-manufacturing joint venture with GET. Subsequent to quarter-end, the parties amended contribution schedules; GET funded a RMB 900 million shareholder loan on April 14, 2017, at 8% interest, for specified facility and development uses. The short-term RMB loan recorded at quarter-end was repaid April 14.
- At quarter-end, the company had $8.9 million of operating lease commitments and $2.1 million of capital commitments. No material legal proceedings were reported.
Outlook, risks and contingencies
Management expected existing cash, cash equivalents and short-term investments to fund operating expenses and capital expenditures for at least 12 months after issuance of the financial statements. This is not a guarantee: the company expected significant increases in R&D and manufacturing spending, anticipated continued losses, and stated that additional funding would be needed for its longer-term development and commercialization plans. It provided no numerical earnings or revenue guidance.
- Key risks include clinical-trial failure or delay, patient-enrollment and safety issues, regulatory uncertainty, manufacturing scale-up and facility delays, and dependence on third-party research and manufacturing providers.
- The company may need additional equity, debt or collaboration financing; funding may be unavailable or dilutive, restrictive, or require concessions of valuable rights.
- Other stated risks include competition and intellectual-property disputes, PRC regulatory and foreign-exchange restrictions, currency movements, and reliance on collaboration milestones. Certain patents relevant to BGB-A317, BGB-3111 and BGB-290 could require licenses if upheld and applicable to commercialization.
- Cash deposits were not protected by statutory or commercial insurance. A hypothetical 100-basis-point interest-rate change was estimated to affect investment-portfolio fair value by $0.9 million.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2017, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the registrant identity: the filing is for BeiGene, Ltd., notwithstanding the “Beone Medicines Ltd.” request metadata.
- Track clinical progress, safety, enrollment and regulatory milestones for the four lead candidates, particularly after the return of BGB-283 rights.
- Monitor cash burn, investment balances and the timing and terms of any additional financing; management’s 12-month liquidity outlook depends on assumptions.
- Verify the Guangzhou joint venture’s final ownership and funding terms, the use and repayment terms of GET’s RMB 900 million loan, and the cost and timing of manufacturing projects.
- Assess potential licensing needs and other intellectual-property exposure for BGB-A317, BGB-3111 and BGB-290.